Navigation Links
Orexigen Resubmits Contrave New Drug Application
Date:12/11/2013

"

By agreement with the FDA, the independent Data Monitoring Committee's summary report of the Light Study interim analysis formed the basis of the resubmission of the NDA. The interim analysis clinical study report (CSR) will be supplied to the FDA within 60 days of the NDA resubmission. The review period for the resubmission is expected to be six months.

About the Light Study
The Contrave Light Study is a double-blind, placebo-controlled cardiovascular outcomes trial that randomized approximately 8,900 patients. The primary objective of the Light Study, which Orexigen is conducting under a Special Protocol Assessment with the FDA at approximately 260 clinical sites in the United States, is to rule out excess cardiovascular risk in overweight and obese patients receiving Contrave. In November 2013 Orexigen announced successful results of the interim analysis of the Light Study, stating that it met the prespecified criteria to exclude a hazard ratio of 2.0, using the upper bound of the 95% confidence interval, for excess risk of major adverse cardiovascular events (MACE) in patients receiving Contrave as compared to placebo.

About Contrave
Contrave (naltrexone sustained release (SR)/bupropion SR) is an investigational medication being evaluated for weight loss and maintenance of weight loss. Prior to initiation of the Light Study, Contrave was studied in clinical trials enrolling more than 4,500 people. In these clinical trials, 53 percent of study participants taking Contrave and 21 percent of those taking placebo lost five percent or more of their body weight over the 12 month trial duration. Many patients saw improvements in cholesterol levels, and blood sugar control. Those who combined Contrave with intensive diet and exercise experienced the most reduction in body weight. There is no guarantee that Contrave will help patients lose weight.

In the Contrave Phase 3 clinical development program, the
'/>"/>

SOURCE Orexigen Therapeutics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Orexigen Therapeutics, Inc. Announces the Closing of its Offering of $115 Million of Convertible Senior Notes
2. Orexigen Therapeutics to Present at the 25th Annual Piper Jaffray Healthcare Conference
3. Orexigen Announces Successful Interim Analysis of Contrave Light Study
4. Orexigen Therapeutics to Host Contrave Light Study Interim Analysis Conference Call and Webcast
5. Orexigen Therapeutics Reports Business and Financial Results for the Third Quarter Ended September 30, 2013
6. Orexigen and Takeda Announce Multiple Contrave Data Presentations at the ObesityWeek Meeting in Atlanta
7. Orexigen Therapeutics Enters Into Agreement with Sanofi to Manufacture Contrave for Territories Outside North America
8. A Balanced Risk-Benefit Profile Will Propel Orexigen/Takedas Contrave to Become the Most Widely Used Emerging Therapy for the Treatment of Obese and Overweight Patients
9. Orexigen Therapeutics Announces Date of Third Quarter 2013 Financial Results Conference Call and Upcoming Presentation at Credit Suisse Healthcare Conference
10. Orexigen Therapeutics to Present at the Bank of America Merrill Lynch Global Healthcare Conference
11. Orexigen Therapeutics Announces European Filing Strategy and Reports Business and Financial Results for the Second Quarter Ended June 30, 2013
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Corporation , a neurodiagnostics medical device company based in ... Forcht Dagi , MD, DmedSc, MPH, MBA, FACS, FRCSEd  was ... " Teo Forcht Dagi is an experienced leader with ... said Remis Bistras , President and CEO of Vittamed. ... entrepreneurial expertise to our Board." Dr. Dagi is ...
(Date:8/29/2014)... , Aug. 29, 2014 Diseases largely eradicated ... generation ago are returning. Measles was declared eliminated in ... 2014 as of August 15—the highest incidence in 20 ... health department declared whooping cough a problem of ... getting sick and dying from these preventable diseases—in part ...
(Date:8/29/2014)... -- ChemImage will present a workshop focused on hyperspectral ... Science Society,s 22 nd International Symposium on ... .  Forensic Scientists will be in attendance ... can bring to examination procedures. ... Development at ChemImage, will host a workshop during ...
Breaking Medicine Technology:Vittamed Adds Prominent Neurosurgeon and Venture Capitalist T. Forcht Dagi to Board of Directors 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 2Vaccines at the Crossroads: Outbreaks On the Rise Across America 3ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 2ChemImage to Discuss Hyperspectral Imaging for Forensic Investigation at the ANZFSS 22nd International Symposium on the Forensic Sciences 3
... The Department of Justice, on behalf of the U.S. Food ... permanent injunction against generic drug manufacturer Ranbaxy in the ... filed against Ranbaxy Laboratories, Ltd., an Indian corporation; its ... Dale Adkisson, senior vice president, head of global quality, ...
... Fine Chemicals LLC (AFC), a wholly owned subsidiary of ... today that is has been granted Registration as a ... Agency (DEA). AFC has been involved in ... under a Researcher,s License from the DEA.  Recent facilities ...
Cached Medicine Technology:Department of Justice files consent decree of permanent injunction against Ranbaxy 2Department of Justice files consent decree of permanent injunction against Ranbaxy 3Department of Justice files consent decree of permanent injunction against Ranbaxy 4AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 2AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 3AMPAC Fine Chemicals Expands Into Controlled Substance Manufacturing 4
(Date:8/30/2014)... 2014 "My niece developed a nighttime ... any moment, her fever might get worse," said an ... well aware of how she was doing, I developed ... to continuously monitor a child's temperature. The unit instantly ... ensures that prompt medical care can be given, which ...
(Date:8/30/2014)... Transvenous lead extraction (TLE) is clinically successful in more ... European Lead Extraction ConTRolled (ELECTRa) registry presented for the ... Maria Grazia Bongiorni, chair of the registry,s executive committee. ... electronic devices (CIED) implant procedures has grown in recent ... has increased and leads are often the cause. TLE ...
(Date:8/30/2014)... August 30, 2014 The new review published ... was created by Karen Brimeyer, who wanted to make her ... , This guide is now easy to find in the ... In this guide, the author of the new method shares ... , Daily Gossip writes in its review that the leaky ...
(Date:8/30/2014)... August 30, 2014 Jake W., 18, is ... in the Back2Basics Outdoor Adventures transition program known ... high school so I can actually start on a real ... math, and I'm done.” , He has six months of ... program. Most clients choose to continue on to the Beyond ...
(Date:8/30/2014)... August 30, 2014 As 500 Zoloft lawsuits ... when give to pregnant mothers, Wright & Schulte LLC recently ... M. Rufe. The remand in the Zoloft lawsuits ... 18 states and are involved in one SSRI lawsuit ... have their Zoloft birth defect lawsuit sent back to the ...
Breaking Medicine News(10 mins):Health News:Transvenous lead extraction clinically successful in 98 percent of cases 2Health News:Transvenous lead extraction clinically successful in 98 percent of cases 3Health News:Leaky Gut Cure Review Reveals Unique Method to Stop Chronic Symptoms 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 2Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 3Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 4Health News:Group of Plaintiffs in Zoloft Lawsuit Alleging SSRI Caused Birth Defect Are Granted Remand 5
... Health and Consumer Advocates Launch Statewide Campaign Aimed at ... 4 As the economy worsens, soaring health insurance ... number of individuals and businesses struggling when it comes ... the state converged on the State Capitol, joining with ...
... the Veterans of Foreign Wars of the U.S. wants ... that would bill veterans with private health insurance for ... wounds. "It is unconscionable to pass along the ... the VFW,s Glen M. Gardner Jr., a Vietnam veteran ...
... N.J., March 4 BIO-key International, Inc. (OTC Bulletin ... finger-based biometric identification solutions, today announced that on or ... United States District Court for the Southern District of ... two of the Company,s investors, Longview Special Finance, Inc. ...
... 4 The U.S. Supreme Court,s ruling in Wyeth ... for patients and public health in general. Patients are ... prescription medications -- set by the medical and scientific experts ... lay juries are permitted to second-guess the experts at FDA ...
... bacterial defenses, making antibiotics more effective , , ... say they,ve engineered a virus that disables the ... of antibiotics. , The scientists said this ... to antibiotics and kill bacteria that have already ...
... and younger have higher rates of their cancer returning ... stage of cancer, and their risk of recurrence is ... according to a March 1 study in the ... of the American Society for Radiation Oncology (ASTRO)., Previous ...
Cached Medicine News:Health News:Illinois Advocates Take on Health Insurance Industry 2Health News:Illinois Advocates Take on Health Insurance Industry 3Health News:VFW Against VA Collection Increase Proposal 2Health News:BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 2Health News:BIO-key to Respond in Court to a Lawsuit Filed by Two Investors 3Health News:Wyeth Comments on U.S. Supreme Court Ruling in Levine Preemption Case 2Health News:Engineered Viruses Could Battle Superbugs 2Health News:Younger breast cancer patients have greater chance of recurrence 2
Straight shafts with 4 mm jaws. Serrated handle with dull finish. Jaws straight....
Double-ended. 10 mm sickle shaped blade. 27 mm blunt, curved double-edged blade....
25 mm blunt, double-edged blade. Flat handle....
Fixed smooth rod which slides on skin. Designated most popular model or size....
Medicine Products: